Zentalis Pharmaceuticals, Inc. Net Change in Cash
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Net Change in Cash of -$11.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$4.07M, a 150.64% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $8.03M, a 16.18% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $9.58M.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$6.79M.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $2.09M, a 63.95% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $5.81M.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$14.98M.
- Zentalis Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$16.89M, a 367.51% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.21M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$4.07M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $2.09M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $5.17M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $3.70M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $8.03M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $5.81M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $13.23M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $8.94M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $9.58M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$14.98M 10-K · filed 2026-03-26 | |||
| 2023-09-30 | $67.68M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $223.49M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$6.79M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$16.89M 10-K · filed 2025-03-26 | |||
| 2022-09-30 | -$17.41M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$4.81M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$29.14M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $6.31M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$12.20M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$3.84M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$24.01M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$11.22M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $26.38M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $28.94M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$3.43M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $42.34M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $55.62M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$16.17M 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | -$9.05M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |